EU vs US: Which Medtech Launch Market Offers Best Returns?
This article was originally published in Clinica
Executive Summary
The global regulatory environment is both dynamic and fluid as different countries systems evolve to meet ever changing technological demands and to reflect experience gained. Throughout the history of the EU’s Medical Device Directives, the US has been perceived to be a tougher market to crack than the EU from the regulatory standpoint. However, this position may no longer be so clear-cut. Amanda Maxwell spoke with experienced medtech investor, Thierry Chignon, who views the US to be more attractive than it has been ever before.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.